Design, synthesis and biological evaluation of Schiff’s base derivatives as multifunctional agents for the treatment of Alzheimer’s disease

被引:0
作者
Jian Shi
Yi Zhou
Keren Wang
Qinge Ma
Rongrui Wei
Qingfeng Li
Yiyang Zhao
Zhanpin Qiao
Shuang Liu
Yumin Leng
Wenmin Liu
Zhipei Sang
机构
[1] Nanyang Normal University,College of Chemistry and Pharmaceutical Engineering
[2] Jiangxi University of Traditional Chinese Medicine,State Key Laboratory of Innovative Drugs and High Efficiency Energy Saving and Consumption Reduction Pharmaceutical Equipment
[3] Nanyang Normal University,Foreign Languages School
[4] Nanyang Normal University,College of Physics and Electronic Engineering
来源
Medicinal Chemistry Research | 2021年 / 30卷
关键词
Alzheimer’s disease; Schiff’s base derivatives; Multifunctional agents; Blood barrier permeability; Drug-like property;
D O I
暂无
中图分类号
学科分类号
摘要
A series of Schiff’s base derivatives was rationally designed, synthesized, and evaluated as multi-function agents for the treatment of Alzheimer’s disease (AD). The results revealed that compound 3b was a novel multifunctional agent. It acted as a highly selective monoamine oxidase-B inhibitor (IC50 = 8.4 nM), which was explained by the docking study. Compound 3b also was an antioxidant agent (2.3 eq) and could significantly inhibit self-induced Aβ1-42 aggregation (31.8%). Meanwhile, compound 3b was a selective metal chelator and could inhibit Cu2+-induced Aβ1-42 aggregation (62.3%). Furthermore, compound 3b presented good neuroprotective effects on H2O2-induced PC12 cell injury. More importantly, compound demonstrated good blood brain barrier permeability and druglike properties. Therefore, compound 3b, a promising multi-targeted active molecule, offers an attractive starting point for further study in the drug-discovery process against AD.[graphic not available: see fulltext]
引用
收藏
页码:624 / 634
页数:10
相关论文
共 122 条
[1]  
Citron M(2010)Alzheimer’s disease: strategies for disease modification Nat Rev Drug Discov 9 387-98
[2]  
Fang J(2015)Discovery of multitarget-directed ligands against Alzheimer’s disease through systematic prediction of chemical-protein interactions J Chem Inf Model 55 149-64
[3]  
Li Y(2019)Multi-target design strategies for the improved treatment of Alzheimer’s disease Eur J Med Chem 176 228-47
[4]  
Liu R(2018)Multi-target directed drugs as a modern approach for drug design towards Alzheimer’s disease: an update Curr Med Chem 25 3491-525.
[5]  
Pang X(2019)Alzheimer’s disease drug development pipeline: 2019 Alzheimers Dement (N. Y) 5 272-93
[6]  
Li C(2018)Clinical research on Alzheimer’s disease: progress and perspectives Neurosci Bull 34 1111-8
[7]  
Yang R(2002)The amyloid hypothesis of Alzheimer’s disease: progress and problems on the road to therapeutics Science 297 353-6
[8]  
Zhang P(2019)Targeting amyloid clearance in Alzheimer’s disease as a therapeutic strategy Br J Pharm 176 3447-63
[9]  
Xu S(2017)Cardiac light chain amyloidosis: the role of metal ions in oxidative stress and mitochondrial damage Antioxid Redox Signal 27 567-82
[10]  
Zhu Z(2018)Oxidative stress and the amyloid beta peptide in Alzheimer’s disease Redox Biol 14 450-64